Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 1
Submit an article Journal homepage
2,868
Views
2
CrossRef citations to date
0
Altmetric
Oncology

Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States

Carl SamuelsenBoehringer Ingelheim International GmbH, Ingelheim, Germany; Correspondence[email protected]
,
Jonathan LimBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA;
,
Amanda GolembeskyBoehringer Ingelheim International GmbH, Ingelheim, Germany;
,
Sulena ShresthaSTATinMED Research, Plano, TX, USA
,
Li WangSTATinMED Research, Plano, TX, USA
&
Ingolf GriebschBoehringer Ingelheim International GmbH, Ingelheim, Germany;
Pages 48-53 | Received 17 May 2019, Accepted 16 Jul 2019, Published online: 09 Aug 2019

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
  • Lee DH, Isobe H, Wirtz H, et al. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study. BMC Health Serv Res. 2018;18:147.
  • Institute. NC. Financial burden of cancer care; 2019. Available from: https://progressreport.cancer.gov/after/economic_burden.
  • Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–iv237.
  • NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 1-2019; 2018 [cited 2019 Jul 18]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
  • Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–589.
  • Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454–1466.
  • Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36:2244–2250.
  • Lim J, Samuelsen C, Golembesky A, et al. Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future Oncol. 2019;15:1493–1504.
  • Tung A, Hepp Z, Bansal A, et al. Characterizing health care utilization, direct costs, and comorbidities associated with interstitial cystitis: a retrospective claims analysis. J Manag Care Spec Pharm. 2017;23:474–482.
  • Divino V, Karve S, Gaughan A, et al. Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis. J Comp Eff Res. 2017;6:497–508.
  • Atzinger CB, Guo JJ. Biologic disease-modifying antirheumatic drugs in a national, privately insured population: utilization, expenditures, and price trends. Am Health Drug Benefits. 2017;10:27–36.
  • Machado MA, Bernatsky S, Bessette L, et al. Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based study. BMC Musculoskelet Disord. 2016;17:298.
  • Jalbert J, Gasse C, Bakshi S, et al. Channeling bias in comparative-effectiveness research of newly launched medications: a case study. Value in Health. 2016;19:A184.
  • Ankarfeldt MZ, Thorsted BL, Groenwold RH, et al. Assessment of channeling bias among initiators of glucose-lowering drugs: a UK cohort study. Clin Epidemiol. 2017;9:19–30.
  • de Groot V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003;56:221–229.
  • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
  • Bureau of Labor Statistics. Consumer price index-all urban consumers; medical care; 2018 [cited 2019 Jul 18]. Available from: https://data.bls.gov/cgi-bin/surveymost.
  • Gehrman J, Bjorholt I, Angenete E, et al. Health economic analysis of costs of laparoscopic and open surgery for rectal cancer within a randomized trial (COLOR II). Surg Endosc. 2017;31:1225–1234.
  • Skinner KE, Fernandes AW, Walker MS, et al. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. J Med Econ. 2018;21:192–200.
  • Isla D, De Castro J, Juan O, et al. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinicoecon Outcomes Res. 2017;9:31–38.
  • Streiner DL, Norman GR. The pros and cons of propensity scores. Chest. 2012;142:1380–1382.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.